Merck (MRK) Stock Gets Fair Value Bump As Analysts Split On Vaccine Outlook

Merck’s updated fair value estimate has shifted to US$159.76, compared with US$155.68 previously, which effectively nudges implied price targets higher for investors tracking intrinsic value. This move sits alongside a split in recent analyst commentary, with some pointing to the cancer vaccine partnership and broader oncology pipeline as support for higher targets, while others flag concerns about valuation and future earnings pressure. As you read on, you will see how this evolving...